These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30174165)

  • 21. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
    Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
    J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients.
    Javaheri A; Molina M; Zamani P; Rodrigues A; Novak E; Chambers S; Stutman P; Maslanek W; Williams M; Lilly SM; Heeger P; Sayegh MH; Chandraker A; Briscoe DM; Daly KP; Starling R; Ikle D; Christie J; Rame JE; Goldberg LR; Billheimer J; Rader DJ
    J Heart Lung Transplant; 2016 Nov; 35(11):1295-1302. PubMed ID: 27498384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients.
    Steigerwalt SP; Brar N; Dhungel A; Butcher D; Steigerwalt S; El-Ghouroury M; Provenzano R
    Transplant Proc; 2009 Dec; 41(10):4184-7. PubMed ID: 20005365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. De novo cancer avoidance after renal transplantation: A case-control study on low-dose sirolimus combined with a calcineurin inhibitor.
    Chen KH; Lee CY; Wu FL; Yang CY; Yeh CC; Hu RH; Tsai MK
    J Formos Med Assoc; 2015 Jun; 114(6):526-31. PubMed ID: 25843527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppressive effects of conversion from mycophenolate mofetil to everolimus for the development of cardiac allograft vasculopathy in maintenance of heart transplant recipients.
    Watanabe T; Seguchi O; Nishimura K; Fujita T; Murata Y; Yanase M; Sato T; Sunami H; Nakajima S; Hisamatsu E; Sato T; Kuroda K; Hieda M; Wada K; Hata H; Ishibashi-Ueda H; Miyamoto Y; Fukushima N; Kobayashi J; Nakatani T
    Int J Cardiol; 2016 Jan; 203():307-14. PubMed ID: 26523360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
    Kobashigawa JA; Pauly DF; Starling RC; Eisen H; Ross H; Wang SS; Cantin B; Hill JA; Lopez P; Dong G; Nicholls SJ;
    JACC Heart Fail; 2013 Oct; 1(5):389-99. PubMed ID: 24621971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial.
    Weir MR; Pearson TC; Patel A; Peddi VR; Kalil R; Scandling J; Chan L; Baliga P; Melton L; Mulgaonkar S; Waid T; Schaefer H; Youssef N; Anandagoda L; McCollum D; Lawson S; Gordon R
    Transplantation; 2017 Jan; 101(1):157-165. PubMed ID: 26950714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3+ regulatory T cells in heart transplantation.
    Mirza K; Gustafsson F; Gullestad L; Arora S; Andersen C
    Transpl Immunol; 2016 Sep; 38():75-7. PubMed ID: 27260644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
    Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
    Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attenuation of cardiac allograft vasculopathy by sirolimus: Relationship to time interval after heart transplantation.
    Matsuo Y; Cassar A; Yoshino S; Flammer AJ; Li J; Gulati R; Topilsky Y; Raichlin E; Lennon RJ; Lerman LO; Rihal CS; Kushwaha SS; Lerman A
    J Heart Lung Transplant; 2013 Aug; 32(8):784-91. PubMed ID: 23856215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
    Ignjatović L; Hrvacević R; Jovanović D; Kovacević Z; Vavić N; Rabrenović V; Tomić A; Aleksić P; Drasković-Pavlović B; Dujić A; Karan Z; Maksić D
    Vojnosanit Pregl; 2013 Sep; 70(9):848-53. PubMed ID: 24266313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression.
    Raichlin E; Bae JH; Kushwaha SS; Lennon RJ; Prasad A; Rihal CS; Lerman A
    J Am Coll Cardiol; 2009 Apr; 53(15):1279-86. PubMed ID: 19358941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors.
    Yu JH; Kim KW; Kim BM; Chung BH; Cho ML; Choi BS; Park CW; Kim YS; Yang CW
    Korean J Intern Med; 2016 May; 31(3):552-9. PubMed ID: 26968190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conversion to sirolimus in renal transplant recipients: a single-center experience.
    Yelken B; Caliskan Y; Ozkan O; Gorgulu N; Yazici H; Turkmen A; Sever MS
    Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy of everolimus as de novo immunosuppressant on the cardiac allograft vasculopathy in heart transplant recipients.
    Choi HI; Kang DY; Kim MS; Lee SE; Ahn JM; Lee JY; Kim YH; Park DW; Jung SH; Kim JJ
    Atherosclerosis; 2022 Sep; 357():1-8. PubMed ID: 35981436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating progenitor cells are associated with plaque progression and long-term outcomes in heart transplant patients.
    Ozcan I; Toya T; Corban MT; Ahmad A; Loeffler D; Morse D; Lerman LO; Kushwaha SS; Lerman A
    Cardiovasc Res; 2022 Jun; 118(7):1703-1712. PubMed ID: 34132771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
    Alberú J; Pascoe MD; Campistol JM; Schena FP; Rial Mdel C; Polinsky M; Neylan JF; Korth-Bradley J; Goldberg-Alberts R; Maller ES;
    Transplantation; 2011 Aug; 92(3):303-10. PubMed ID: 21792049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.